Most-favoured-nation pricing for prescription drugs in US Medicare: a cohort study.

Hwang TJ, Hediger S, Krishnan A, Cai CL, Kesselheim AS, Vokinger KN

Open source

DOI
10.1016/s0140-6736(26)01555-2
Published
2026 Sep 13
Container
Lancet (London, England)
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/s0140-6736-26-01555-2,
  title = {Most-favoured-nation pricing for prescription drugs in US Medicare: a cohort study.},
  author = {Hwang TJ and Hediger S and Krishnan A and Cai CL and Kesselheim AS and Vokinger KN},
  year = {2026},
  journal = {Lancet (London, England)},
  doi = {10.1016/s0140-6736(26)01555-2},
  url = {https://doi.org/10.1016/s0140-6736(26)01555-2}
}

RIS

TY  - JOUR
TI  - Most-favoured-nation pricing for prescription drugs in US Medicare: a cohort study.
AU  - Hwang TJ
AU  - Hediger S
AU  - Krishnan A
AU  - Cai CL
AU  - Kesselheim AS
AU  - Vokinger KN
PY  - 2026
JO  - Lancet (London, England)
DO  - 10.1016/s0140-6736(26)01555-2
UR  - https://doi.org/10.1016/s0140-6736(26)01555-2
ER  - 

APA

TJ, H., S, H., A, K., CL, C., AS, K., & KN, V. (2026). Most-favoured-nation pricing for prescription drugs in US Medicare: a cohort study.. Lancet (London, England). https://doi.org/10.1016/s0140-6736(26)01555-2

Source records